Nektar Therapeutics (NKTR) Misses Q1 Views on Top and Bottom
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $65.70 +7.74%
Revenue Growth %: -7.1%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: -7.1%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 loss of $0.33, $0.06 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $11.3 million versus the consensus estimate of $17.2 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- CarMax (KMX) Tops Q1 EPS by 35c, Beats on Revenue
- CarMax beats estimates as new strategy drives early results
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
